Replimune, uniQure rise after report FDA chief Makary may be ousted

Rudrabhishek Enterprises

08/05/2026 22:53

Updates

** Shares of biotech firm Replimune REPL.O rise 4.2% to $4.24 in extended trading

** U.S. President Donald Trump is planning to fire U.S. Food and Drug Administration Commissioner Marty Makary, Reuters reports citing sources familiar with the matter

** Makary on Tuesday defended the regulator's decision to not approve REPL's drug Tudriqev for advanced skin cancer

** Last month, the health regulator
declined
 to approve REPL's drug for the second time

** U.S.-listed shares of Dutch gene therapy developer uniQure UQ1.F close 10.4% higher on Friday following the news

** uniQure became the center of controversy when the FDA rejected its Huntington’s disease therapy, citing inadequate data and requesting a new study

** REPL down 26% YTD

(Reporting by Kunal Das and Padmanabhan Ananthan in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))